Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

DiagnaMed Launches “Health GenAI”, a New Division for Generative AI Healthcare Solutions

Focused on Health GenAI and CERVAI, a generative AI brain health platform

DiagnaMed Holdings Corp, a generative AI healthcare solutions company, is pleased to announce the launch of Health GenAI, a new division focused on the development and commercialization of a suite of generative AI ready-made and customizable applications powered by GPT-4 to support the healthcare market in improving patient outcomes, operational workflow and efficiency. The Company expects to launch at least three products from its Health GenAI division this year.

AiThority Interview Insights: AiThority Interview with Darren Guarnaccia, President at Uniform

DiagnaMed is organized to focus on its two divisions, CERVAI™, a generative AI brain health platform, and Health GenAI. According to, generative AI in the healthcare market is set to reach approximately USD 17 billion by 2032, driven by the adoption of automation by healthcare operators in drug discovery and development, medical imaging and diagnostics, personalized medical interventions, and hospitals and clinical decision support systems.

Fabio Chianelli, Chairman of DiagnaMed, commented: “We are passionate about developing new generative AI-powered SaaS products to serve the needs of the healthcare sector. With the launch of our new division, Health GenAI, we are focusing on commercializing at least three generative AI solutions for the healthcare market and on complementing CERVAI™, our generative AI brain health platform.”

Related Posts
1 of 40,569

Read More about AiThority InterviewAiThority Interview with Brett Weigl, SVP and GM, Digital, AI and Journey Analytics at Genesys

As part of its Health GenAI division, the Company recently announced the launch of its first commercial product, a generative AI data collection and analysis solution for the healthcare market, which was born from the development experience and features of CERVAI™. allows licensed medical professionals, hospitals, and life science to create customized forms and surveys with the support of ChatGPT and collect relevant patient data, obtain pre-and-post-visit and treatment feedback, monitor patient progress, and analyze results for decision-making. empowers licensed professionals and clinical researchers to easily and quickly develop forms and surveys that complement their workflow and specific patient and research objectives. In addition, aims to improve user services, workflow, patient outcomes and engagement. The Company is making its minimal viable product version of available to the public with a 7-day f*********.

DiagnaMed Holdings Corp, a generative AI healthcare solutions company, is focused on the development and commercialization of CERVAI™, a proprietary brain health AI platform, and Health GenAI, a suite of generative AI SaaS products for the healthcare market.

 Latest AiThority Interview Insights : AiThority Interview with Mary-Lou Smulders, Chief Marketing Officer at Dedrone

 [To share your insights with us, please write to] 

Comments are closed.